44 results on '"Aragri, Marianna"'
Search Results
2. HCV very late relapse following an atypical viral kinetics in a HIV patient treated for hepatitis C with direct-acting antivirals
- Author
-
Guardigni, Viola, Cento, Valeria, Ianniruberto, Stefano, Badia, Lorenzo, Aragri, Marianna, Conti, Matteo, Perno, Carlo Federico, Viale, Pierluigi, Ceccherini-Silberstein, Francesca, and Verucchi, Gabriella
- Published
- 2018
- Full Text
- View/download PDF
3. Multiple Hepatitis B Virus (HBV) Quasispecies and Immune-Escape Mutations Are Present in HBV Surface Antigen and Reverse Transcriptase of Patients With Acute Hepatitis B
- Author
-
Aragri, Marianna, Alteri, Claudia, Battisti, Arianna, Di Carlo, Domenico, Minichini, Carmine, Sagnelli, Caterina, Bellocchi, Maria Concetta, Pisaturo, Maria Antonietta, Starace, Mario, Armenia, Daniele, Carioti, Luca, Pollicita, Michela, Salpini, Romina, Sagnelli, Evangelista, Perno, Carlo Federico, Coppola, Nicola, and Svicher, Valentina
- Published
- 2016
4. Hepatitis B virus reactivation sustained by a hepatitis B virus surface antigen immune-escape mutant isolate in a patient who was hepatitis B core antibody positive during treatment with sofosbuvir and velpatasvir for hepatitis C virus infection: a case report
- Author
-
Foroghi Biland, Luca, Ferrari, Ludovica, Malagnino, Vincenzo, Teti, Elisabetta, Cerva, Carlotta, Gentile, Adele, Aragri, Marianna, Salpini, Romina, Svicher, Valentina, Andreoni, Massimo, and Sarmati, Loredana
- Published
- 2019
- Full Text
- View/download PDF
5. Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection
- Author
-
Mirabelli, Carmen, Surdo, Matteo, Van Hemert, Formijn, Lian, Zhichao, Salpini, Romina, Cento, Valeria, Cortese, Maria Francesca, Aragri, Marianna, Pollicita, Michela, Alteri, Claudia, Bertoli, Ada, Berkhout, Ben, Micheli, Valeria, Gubertini, Guido, Santoro, Maria Mercedes, Romano, Sara, Visca, Michela, Bernassola, Martina, Longo, Roberta, De Sanctis, Giuseppe Maria, Trimoulet, Pascal, Fleury, Hervè, Marino, Nicoletta, Mazzotta, Francesco, Cappiello, Giuseppina, Spanò, Alberto, Sarrecchia, Cesare, Zhang, Jing Maria, Andreoni, Massimo, Angelico, Mario, Verheyen, Jens, Perno, Carlo Federico, and Svicher, Valentina
- Published
- 2015
- Full Text
- View/download PDF
6. Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome
- Author
-
Cento, Valeria, Di Paolo, Daniele, Di Carlo, Domenico, Micheli, Valeria, Tontodonati, Monica, De Leonardis, Francesco, Aragri, Marianna, Antonucci, Francesco Paolo, Di Maio, Velia Chiara, Mancon, Alessandro, Lenci, Ilaria, Manunta, Alessandra, Taliani, Gloria, Di Biagio, Antonio, Nicolini, Laura Ambra, Nosotti, Lorenzo, Sarrecchia, Cesare, Siciliano, Massimo, Landonio, Simona, Pellicelli, Adriano, Gasbarrini, Adriano, Vecchiet, Jacopo, Magni, Carlo Federico, Babudieri, Sergio, Mura, Maria Stella, Andreoni, Massimo, Parruti, Giustino, Rizzardini, Giuliano, Angelico, Mario, Perno, Carlo Federico, and Ceccherini-Silberstein, Francesca
- Published
- 2015
- Full Text
- View/download PDF
7. Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1–4 in Italy
- Author
-
Bertoli, Ada, Sorbo, Maria Chiara, Aragri, Marianna, Lenci, Ilaria, Teti, Elisabetta, Polilli, Ennio, Di Maio, Velia Chiara, Gianserra, Laura, Biliotti, Elisa, Masetti, Chiara, Magni, Carlo F., Babudieri, Sergio, Nicolini, Laura A., Milana, Martina, Cacciatore, Pierluigi, Sarmati, Loredana, Pellicelli, Adriano, Paolucci, Stefania, Craxì, Antonio, Morisco, Filomena, Palitti, Valeria Pace, Siciliano, Massimo, Coppola, Nicola, Iapadre, Nerio, Puoti, Massimo, Rizzardini, Giuliano, Taliani, Gloria, Pasquazzi, Caterina, Andreoni, Massimo, Parruti, Giustino, Angelico, Mario, Perno, Carlo Federico, Cento, Valeria, Ceccherini-Silberstein, Francesca, and HCV Virology Italian Resistance Network (VIRONET-C)
- Published
- 2018
- Full Text
- View/download PDF
8. Evidence of Spontaneous Post-transplant HCV Eradication in Two Failed DAA Treatments Awaiting Liver Transplantation
- Author
-
Lenci, Ilaria, Bosa, Alessandra, Milana, Martina, Baiocchi, Leonardo, Antonucci, Francesco Paolo, Aragri, Marianna, Ceccherini-Silberstein, Francesca, Perno, Carlo Federico, Tisone, Giuseppe, and Angelico, Mario
- Published
- 2017
- Full Text
- View/download PDF
9. Resistance and phylogenetic analysis in HCV-2c infected patients within the Italian network VIRONET-C
- Author
-
Di Maio, Velia Chiara, Barbaliscia, Silvia, Fabeni, Lavinia, Teti, Elisabetta, Paolucci, Stefania, Minichini, Carmine, Aragri, Marianna, La Rosa, Katia Yu, Pasquazzi, Caterina, Milana, Martina, Foroghi, Luca, Pollicino, Teresa, Licata, Anna, Pieri, Alessandro, Palitti, Valeria Pace, Bruzzone, Bianca, Valeria Micheli, Bertoli, Ada, Baiocchi, Leonardo, Callegaro, Maria Paola, Carioti, Luca, Pellicelli, Adriano, Morisco, Filomena, Gulminetti, Roberto, Novati, Stefano, Lichtner, Miriam, Mastroianni, Claudio M., Di Lorenzo, Francesco, Andreone, Pietro, Rossetti, Barbara, Marenco, Simona, Taliani, Gloria, Boeri, Enzo, Hasson, Hamid, Monno, Laura, Nicolini, Laura Ambra, Landonio, Simona, Paternoster, Claudio, Puoti, Massimo, Babudieri, Sergio, Quartini, Mariano, Iapadre, Nerio, Cozzolongo, Raffaele, Sangiovanni, Vincenzo, Parruti, Giustino, Sarmati, Loredana, Coppola, Nicola, Zazzi, Maurizio, Raimondo, Giovanni, Mario, Angelico, Perno, Carlo-Federico, Andreoni, Massimo, Craxi, Antonio, and Silberstein, Francesca Ceccherini
- Subjects
Hepatology - Published
- 2020
- Full Text
- View/download PDF
10. Hepatitis C Virus Gene Sequencing as a Tool for Precise Genotyping in the Era of New Direct Antiviral Agents
- Author
-
Ceccherini Silberstein, Francesca, Di Maio, Velia Chiara, Aragri, Marianna, Ciotti, Marco, Cento, Valeria, and Perno, Carlo Federico
- Published
- 2016
- Full Text
- View/download PDF
11. Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression
- Author
-
Salpini, Romina, Colagrossi, Luna, Bellocchi, Maria Concetta, Surdo, Matteo, Becker, Christina, Alteri, Claudia, Aragri, Marianna, Ricciardi, Alessandra, Armenia, Daniele, Pollicita, Michela, Di Santo, Fabiola, Carioti, Luca, Louzoun, Yoram, Mastroianni, Claudio Maria, Lichtner, Miriam, Paoloni, Maurizio, Esposito, Mariarosaria, DʼAmore, Chiara, Marrone, Aldo, Marignani, Massimo, Sarrecchia, Cesare, Sarmati, Loredana, Andreoni, Massimo, Angelico, Mario, Verheyen, Jens, Perno, Carlo-Federico, and Svicher, Valentina
- Published
- 2015
- Full Text
- View/download PDF
12. Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir/pibrentasvir regimen
- Author
-
de Salazar, Adolfo, Dietz, Julia, di Maio, Velia Chiara, Vermehren, Johannes, Paolucci, Stefania, Müllhaupt, Beat, Coppola, Nicola, Cabezas, Joaquín, Stauber, Rudolf E, Puoti, Massimo, Arenas Ruiz Tapiador, Juan Ignacio, Graf, Christiana, Aragri, Marianna, Jimenez, Miguel, Callegaro, Annapaola, Pascasio Acevedo, Juan Manuel, Macias Rodriguez, Manuel Alberto, Rosales Zabal, Jose Miguel, Micheli, Valeria, Garcia Del Toro, Miguel, Téllez, Francisco, García, Federico, Sarrazin, Christoph, Ceccherini-Silberstein, Francesca, HCV Virology Italian Resistance Network (VIRONET C), De Santis, Adriano, de Salazar, Adolfo, Dietz, Julia, di Maio, Velia Chiara, Vermehren, Johanne, Paolucci, Stefania, Müllhaupt, Beat, Coppola, Nicola, Cabezas, Joaquín, Stauber, Rudolf E, Puoti, Massimo, Arenas Ruiz Tapiador, Juan Ignacio, Graf, Christiana, Aragri, Marianna, Jimenez, Miguel, Callegaro, Annapaola, Pascasio Acevedo, Juan Manuel, Macias Rodriguez, Manuel Alberto, Rosales Zabal, Jose Miguel, Micheli, Valeria, Garcia Del Toro, Miguel, Téllez, Francisco, García, Federico, Sarrazin, Christoph, Ceccherini-Silberstein, Francesca, and University of Zurich
- Subjects
Cyclopropanes ,0301 basic medicine ,Aminoisobutyric Acids ,Pyrrolidines ,Sofosbuvir ,viruses ,Hepacivirus ,Viral Nonstructural Proteins ,Settore MED/07 ,0302 clinical medicine ,Germany ,Genotype ,Prevalence ,Pharmacology (medical) ,To investigate resistance-associated substitutions (RASs) as well as retreatment efficacies in a large cohort of European patients with failure of glecaprevir/pibrentasvir ,Sulfonamides ,virus diseases ,Pibrentasvir ,10219 Clinic for Gastroenterology and Hepatology ,Infectious Diseases ,Italy ,Retreatment ,030211 gastroenterology & hepatology ,medicine.drug ,Microbiology (medical) ,medicine.medical_specialty ,Proline ,Lactams, Macrocyclic ,Voxilaprevir ,610 Medicine & health ,Antiviral Agents ,03 medical and health sciences ,Leucine ,Quinoxalines ,Internal medicine ,Drug Resistance, Viral ,medicine ,Humans ,NS5A ,Retrospective Studies ,Pharmacology ,business.industry ,Glecaprevir ,biochemical phenomena, metabolism, and nutrition ,digestive system diseases ,Regimen ,030104 developmental biology ,Spain ,Benzimidazoles ,business ,Velpatasvir - Abstract
Objectives To investigate resistance-associated substitutions (RASs) as well as retreatment efficacies in a large cohort of European patients with failure of glecaprevir/pibrentasvir. Methods Patients were identified from three European Resistance Reference centres in Spain, Italy and Germany. Sequencing of NS3, NS5A and NS5B was conducted and substitutions associated with resistance to direct antiviral agents were analysed. Clinical and virological parameters were documented retrospectively and retreatment efficacies were evaluated. Results We evaluated 90 glecaprevir/pibrentasvir failures [3a (n = 36), 1a (n = 23), 2a/2c (n = 20), 1b (n = 10) and 4d (n = 1)]. Ten patients were cirrhotic, two had previous exposure to PEG-interferon and seven were coinfected with HIV; 80 had been treated for 8 weeks. Overall, 31 patients (34.4%) failed glecaprevir/pibrentasvir without any NS3 or NS5A RASs, 62.4% (53/85) showed RASs in NS5A, 15.6% (13/83) in NS3 and 10% (9/90) in both NS5A and NS3. Infection with HCV genotypes 1a and 3a was associated with a higher prevalence of NS5A RASs. Patients harbouring two (n = 34) or more (n = 8) RASs in NS5A were frequent. Retreatment was initiated in 56 patients, almost all (n = 52) with sofosbuvir/velpatasvir/voxilaprevir. The overall sustained virological response rate was 97.8% in patients with end-of-follow-up data available. Conclusions One-third of patients failed glecaprevir/pibrentasvir without resistance. RASs in NS5A were more prevalent than in NS3 and were frequently observed as dual and triple combination patterns, with a high impact on NS5A inhibitor activity, particularly in genotypes 1a and 3a. Retreatment of glecaprevir/pibrentasvir failures with sofosbuvir/velpatasvir/voxilaprevir achieved viral suppression across all genotypes.
- Published
- 2020
13. An Outbreak of Hepatitis C Virus Infection Among Transfused Thalassemia Patients: Root Cause Analysis, Phylogenetic Epidemiology and Antiviral Therapy
- Author
-
Mazzucco, Walter, primary, Di Maio, Velia Chiara, additional, Bronte, Fabrizio, additional, Fabeni, Lavinia, additional, Pipitone, Rosaria, additional, Grimaudo, Stefania, additional, Ferraro, Donatella, additional, Marotta, Claudia, additional, Aragri, Marianna, additional, Macaluso, Maurizio, additional, Di Raimondo, Francesco, additional, Ceccherini, Francesca, additional, and Di Marco, Vito, additional
- Published
- 2021
- Full Text
- View/download PDF
14. Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?
- Author
-
Andreone, Pietro, Andreoni, Massimo, Angelico, Mario, Babudieri, Sergio, Barbarini, Giorgio, Boccaccio, Vincenzo, Boglione, Lucio, Bolis, Matteo, Bonora, Stefano, Borghi, Vanni, Brancaccio, Giuseppina, Bruno, Savino, Cacciatore, Pierluigi, Calvaruso, Vincenza, Caporaso, Nicola, Ciaccio, Antonio, Ciancio, Alessia, Colombatto, Piero, Cozzolongo, Raffaele, Craxì, Antonio, D'Ambrosio, Cecilia, D'Ettorre, Gabriella, De Luca, Andrea, Di Biagio, Antonio, Di Perri, Giovanni, Francioso, Simona, Gaeta, Giovanni Battista, Giorgini, Alessia, Grieco, Antonio, Gubertini, Guido, Gulminetti, Roberto, Lambiase, Lara, Lenci, Ilaria, Lichtner, Miriam, Maida, Ivana, Marenco, Simona, Marinaro, Letizia, Maserati, Renato, Masetti, Chiara, Melis, Michela, Meregalli, Elisa, Micheli, Valeria, Morisco, Filomena, Niero, Fosca, Nicolini, Laura Ambra, Palitti, Valeria Pace, Paoloni, Maurizio, Parruti, Giustino, Pasquazzi, Caterina, Pellicelli, Adriano, Polilli, Ennio, Ponti, Maria Laura, Puoti, Massimo, Rendina, Maria, Rizzardini, Giuliano, Rossetti, Barbara, Ruggiero, Tina, Sangiovanni, Vincenzo, Starace, Mario, Sticchi, Laura, Tarquini, Pierluigi, Toniutto, Pierluigi, Vullo, Vincenzo, Di Maio, Velia Chiara, Cento, Valeria, Aragri, Marianna, Paolucci, Stefania, Pollicino, Teresa, Coppola, Nicola, Bruzzone, Bianca, Ghisetti, Valeria, Zazzi, Maurizio, Brunetto, Maurizia, Bertoli, Ada, Barbaliscia, Silvia, Galli, Silvia, Gennari, William, Baldanti, Fausto, Raimondo, Giovanni, Perno, Carlo Federico, and Ceccherini-Silberstein, Francesca
- Published
- 2018
- Full Text
- View/download PDF
15. A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition In Vitro
- Author
-
Salpini, Romina, primary, Piermatteo, Lorenzo, additional, Battisti, Arianna, additional, Colagrossi, Luna, additional, Aragri, Marianna, additional, Yu La Rosa, Katia, additional, Bertoli, Ada, additional, Saccomandi, Patrizia, additional, Lichtner, Miriam, additional, Marignani, Massimo, additional, Maylin, Sarah, additional, Delaugerre, Constance, additional, Morisco, Filomena, additional, Coppola, Nicola, additional, Marrone, Aldo, additional, Iapadre, Nerio, additional, Cerva, Carlotta, additional, Aquaro, Stefano, additional, Angelico, Mario, additional, Sarmati, Loredana, additional, Andreoni, Massimo, additional, Verheyen, Jens, additional, Ceccherini-Silberstein, Francesca, additional, Levrero, Massimo, additional, Perno, Carlo Federico, additional, Belloni, Laura, additional, and Svicher, Valentina, additional
- Published
- 2020
- Full Text
- View/download PDF
16. NS5A Gene Analysis by Next Generation Sequencing in HCV Nosocomial Transmission Clusters of HCV Genotype 1b Infected Patients
- Author
-
Bellocchi, Maria Concetta, primary, Aragri, Marianna, additional, Carioti, Luca, additional, Fabeni, Lavinia, additional, Pipitone, Rosaria Maria, additional, Brancaccio, Giuseppina, additional, Sorbo, Maria Chiara, additional, Barbaliscia, Silvia, additional, Di Maio, Velia Chiara, additional, Bronte, Fabrizio, additional, Grimaudo, Stefania, additional, Mazzucco, Walter, additional, Frigeri, Ferdinando, additional, Cantone, Marco, additional, Pinto, Antonio, additional, Perno, Carlo Federico, additional, Craxì, Antonio, additional, Gaeta, Giovanni Battista, additional, Di Marco, Vito, additional, and Ceccherini-Silberstein, Francesca, additional
- Published
- 2019
- Full Text
- View/download PDF
17. SAT-190-Specific genetic elements in HBsAg C-terminus profoundly affect HBsAg levels in vivo, hamper HBsAg secretion in vitro and alter HBsAg structural stability in HBeAg-negative chronic HBV genotype D infection
- Author
-
Piermatteo, Lorenzo, primary, Battisti, Arianna, additional, Carioti, Luca, additional, Anastasiou, Olympia, additional, Gill, Upkar S., additional, Colagrossi, Luna, additional, Bertoli, Ada, additional, Aragri, Marianna, additional, Iuvara, Alessandra, additional, Malagnino, Vincenzo, additional, Cerva, Carlotta, additional, Lichtner, Miriam, additional, Mastroianni, Claudio M., additional, Sanctis, Giuseppe Maria De, additional, Maurizio, Paoloni, additional, Marignani, Massimo, additional, Pasquazzi, Caterina, additional, Iapadre, Nerio, additional, Mari, Terenzio, additional, Parruti, Giustino, additional, Vecchiet, Jacopo, additional, Sarmati, Loredana, additional, Andreoni, Massimo, additional, Mario, Angelico, additional, Grelli, Sandro, additional, Kennedy, Patrick, additional, Verheyen, Jens, additional, Silberstein, Francesca Ceccherini, additional, Perno, Carlo Federico, additional, Svicher, Valentina, additional, and Salpini, Romina, additional
- Published
- 2019
- Full Text
- View/download PDF
18. THU-117-Evaluation of risk factors associated with failure to a first-line NS5A-containing regimen in HCV-infected patients naive to direct acting antivirals: Particular focus on natural resistance
- Author
-
Barbaliscia, Silvia, primary, Maio, Velia Chiara Di, additional, Teti, Elisabetta, additional, Aragri, Marianna, additional, Paolucci, Stefania, additional, Masetti, Chiara, additional, D’ambrosio, Roberta, additional, Polilli, Ennio, additional, Palitti, Valeria Pace, additional, Fiorentino, Gianluca, additional, Cento, Valeria, additional, Scutari, Rossana, additional, Bruzzone, Bianca, additional, Calvaruso, Vincenza, additional, Nicola, Coppola, additional, Gaeta, Giovanni Battista, additional, Morsica, Giulia, additional, Ghisetti, Valeria, additional, Bertoli, Ada, additional, Milana, Martina, additional, Foroghi, Luca, additional, Nicolini, Laura Ambra, additional, Borghi, Vanni, additional, Campoli, Riccardo, additional, Galli, Silvia, additional, Magni, Carlo Federico, additional, Micheli, Valeria, additional, Boccaccio, Vincenzo, additional, Maserati, Renato, additional, Bonora, Stefano, additional, Iapadre, Nerio, additional, Morisco, Filomena, additional, Siciliano, Massimo, additional, Andreone, Pietro, additional, Lichtner, Miriam, additional, Paba, Pierpaolo, additional, Sarmati, Loredana, additional, Puoti, Massimo, additional, Craxi, Antonio, additional, Pellicelli, Adriano, additional, Babudieri, Sergio, additional, Rizzardini, Giuliano, additional, Taliani, Gloria, additional, Lampertico, Pietro, additional, Pasquazzi, Caterina, additional, Parruti, Giustino, additional, Mario, Angelico, additional, Andreoni, Massimo, additional, Perno, Carlo Federico, additional, and Silberstein, Francesca Ceccherini, additional
- Published
- 2019
- Full Text
- View/download PDF
19. SAT-159-Genetic determinants in critical domains of NS5A are associated with genotype 1b HCV-induced hepatocellular carcinoma
- Author
-
Salpini, Romina, primary, Alkhatib, Mohammad, additional, Maio, Velia Chiara Di, additional, Murtas, Valentina De, additional, Aragri, Marianna, additional, Scutari, Rossana, additional, Sacco, Angelica, additional, Polilli, Ennio, additional, Masetti, Chiara, additional, Barbaliscia, Silvia, additional, Bertoli, Ada, additional, Cento, Valeria, additional, Calvaruso, Vincenza, additional, Morisco, Filomena, additional, Palitti, Valeria Pace, additional, Pasquazzi, Caterina, additional, Francioso, Simona, additional, Sozio, Federica, additional, Pieri, Alessandro, additional, Cacciatore, Pierluigi, additional, Babudieri, Sergio, additional, Teti, Elisabetta, additional, Mussini, Cristina, additional, Parruti, Giustino, additional, Borghi, Vanni, additional, Lenci, Ilaria, additional, Craxi, Antonio, additional, Andreoni, Massimo, additional, Mario, Angelico, additional, Maida, Ivana Rita, additional, Santoro, Maria, additional, Svicher, Valentina, additional, Perno, Carlo-federico, additional, and Silberstein, Francesca Ceccherini, additional
- Published
- 2019
- Full Text
- View/download PDF
20. THU-133-Resistance-guided retreatment of HCV infected patients with a previous failure to an NS5A inhibitor-containing regimen: Italian real life experience
- Author
-
Maio, Velia Chiara Di, primary, Aragri, Marianna, additional, Masetti, Chiara, additional, Paolucci, Stefania, additional, Bruzzone, Bianca, additional, Degasperi, Elisabetta, additional, Barbaliscia, Silvia, additional, Pollicino, Teresa, additional, Minichini, Carmine, additional, Calvaruso, Vincenza, additional, Rendina, Maria Grazia, additional, Cento, Valeria, additional, Teti, Elisabetta, additional, Micheli, Valeria, additional, Ghisetti, Valeria, additional, Polilli, Ennio, additional, Palitti, Valeria Pace, additional, Landonio, Simona, additional, Lenci, Ilaria, additional, Donnarumma, Laura, additional, Nicolini, Laura Ambra, additional, Bertoli, Ada, additional, Pasquazzi, Caterina, additional, Callegaro, Maria Paola, additional, Morisco, Filomena, additional, Cenderrello, Giovanni, additional, Marenco, Simona, additional, Gulminetti, Roberto, additional, Novati, Stefano, additional, Andreone, Pietro, additional, Ciancio, Alessia, additional, Sangiovanni, Vincenzo, additional, Cuomo, Nunzia, additional, Morsica, Giulia, additional, Borghi, Vanni, additional, Maida, Ivana Rita, additional, Brunetto, Maurizia, additional, Cozzolongo, Raffaele, additional, Santis, Adriano De, additional, Lichtner, Miriam, additional, Babudieri, Sergio, additional, Taliani, Gloria, additional, Santantonio, Teresa, additional, Paternoster, Claudio, additional, Ganga, Roberto, additional, Puoti, Massimo, additional, Rizzardini, Giuliano, additional, Pellicelli, Adriano, additional, Lampertico, Pietro, additional, Parruti, Giustino, additional, Nicola, Coppola, additional, Zazzi, Maurizio, additional, Raimondo, Giovanni, additional, Andreoni, Massimo, additional, Craxi, Antonio, additional, Mario, Angelico, additional, Perno, Carlo Federico, additional, and Ceccherini, Silberstein Francesca, additional
- Published
- 2019
- Full Text
- View/download PDF
21. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies
- Author
-
Di Maio, Velia C., Cento, Valeria, Lenci, Ilaria, Aragri, Marianna, Rossi, Piera, Barbaliscia, Silvia, Melis, Michela, Verucchi, Gabriella, Magni, Carlo F., Teti, Elisabetta, Bertoli, Ada, Antonucci, Francescopaolo, Bellocchi, Maria C., Micheli, Valeria, Masetti, Chiara, Landonio, Simona, Francioso, Simona, Santopaolo, Francesco, Pellicelli, Adriano M., Calvaruso, Vincenza, Gianserra, Laura, Siciliano, Massimo, Romagnoli, Dante, Cozzolongo, Raffaele, Grieco, Antonio, Vecchiet, Jacopo, Morisco, Filomena, Merli, Manuela, Brancaccio, Giuseppina, Di Biagio, Antonio, Loggi, Elisabetta, Mastroianni, Claudio Maria, Pace Palitti, Valeria, Tarquini, Pierluigi, Puoti, Massimo, Taliani, Gloria, Sarmati, Loredana, Picciotto, Antonino, Vullo, Vincenzo, Caporaso, Nicola, Paoloni, Maurizio, Pasquazzi, Caterina, Rizzardini, Giuliano, Parruti, Giustino, Craxì, Antonio, Babudieri, Sergio, Andreoni, Massimo, Angelico, Mario, Perno, Carlo F., Ceccherini Silberstein, Francesca, Mariani, R., Iapadre, N., Grimaldi, A., Cozzolongo, R., Andreone, P., Verucchi, G., Menzaghi, B., Quirino, T., Pisani, V., Torti, MARIA CHIARA, Vecchiet, J., Bruzzone, B., De Maria, A., Marenco, S., Nicolini, L. A., Viscoli, C., Casinelli, K., Delle Monache, M., Lichtner, Miriam, Aghemo, A., Boccaccio, V., Bruno, S., Cerrone, M., Colombo, M., D'Arminio Monforte, A., Danieli, E., Donato, F., Gubertini, G., Lleo, A., Magni, C. F., Mancon, A., Monico, S., Niero, F., Russo, M. L., Gnocchi, M., Orro, A., Milanesi, L., Baldelli, E., Bertolotti, M., Borghi, V., Mussini, C., Brancaccio, G., Gaeta, G. B., Lembo, V., Sangiovanni, V., Di Marco, V., Mazzola, A., Petta, S., D'Amico, E., Cacciatore, P., Consorte, A., Pieri, A., Polilli, E., Sozio, F., Antenucci, F., Aragri, M., Baiocchi, L., Barbaliscia, S., Biliotti, Elisa, Biolato, M., Carioti, L., Ceccherini Silberstein, F., Cerasari, G., Cerva, C., Ciotti, M., D'Ambrosio, C., D'Ettorre, G., De Leonardis, F., De Sanctis, A., Di Maio, V. C., Di Paolo, D., Furlan, Caterina, Gallo, P., Gasbarrini, A., Giannelli, V., Grieco, S., Lambiase, L., Lattanzi, B., Lenci, I., Lula, R., Malagnino, V., Manuelli, M., Miglioresi, L., Milana, M., Moretti, A., Nosotti, L., Palazzo, Donatella, Pellicelli, A., Romano, M., Sarrecchia, C., Sforza, D., Sorbo, M. C., Spaziante, M., Svicher, V., Tisone, G., Vespasiani Gentilucci, U., D'Adamo, G., Mangia, A., Maida, I., Mura, M. S., Falconi, L., Di Giammartino, D., Di Maio, V., Cento, V., Lenci, I., Aragri, M., Rossi, P., Barbaliscia, S., Melis, M., Verucchi, G., Magni, C., Teti, E., Bertoli, A., Antonucci, F., Bellocchi, M., Micheli, V., Masetti, C., Landonio, S., Francioso, S., Santopaolo, F., Pellicelli, A., Calvaruso, V., Gianserra, L., Siciliano, M., Romagnoli, D., Cozzolongo, R., Grieco, A., Vecchiet, J., Morisco, F., Merli, M., Brancaccio, G., Di Biagio, A., Loggi, E., Mastroianni, C., Pace Palitti, V., Tarquini, P., Puoti, M., Taliani, G., Sarmati, L., Picciotto, A., Vullo, V., Caporaso, N., Paoloni, M., Pasquazzi, C., Rizzardini, G., Parruti, G., Craxã¬, A., Babudieri, S., Andreoni, M., Angelico, M., Perno, C., Ceccherini-Silberstein, F., Mariani, R., Iapadre, N., Grimaldi, A., Andreone, P., Menzaghi, B., Quirino, T., Pisani, V., Torti, C., Bruzzone, B., De Maria, A., Marenco, S., Nicolini, L., Viscoli, C., Casinelli, K., Delle Monache, M., Lichtner, M., Aghemo, A., Boccaccio, V., Bruno, S., Cerrone, M., Colombo, M., D'Arminio Monforte, A., Danieli, E., Donato, F., Gubertini, G., Lleo, A., Mancon, A., Monico, S., Niero, F., Russo, M., Gnocchi, M., Orro, A., Milanesi, L., Baldelli, E., Bertolotti, M., Borghi, V., Mussini, C., Gaeta, G., Lembo, V., Sangiovanni, V., DI MARCO, V., Mazzola, A., Petta, S., D'Amico, E., Cacciatore, P., Consorte, A., Pieri, A., Polilli, E., Sozio, F., Antenucci, F., Baiocchi, L., Biliotti, E., Biolato, M., Carioti, L., Cerasari, G., Cerva, C., Ciotti, M., D'Ambrosio, C., D'Ettorre, G., De Leonardis, F., De Sanctis, A., Di Paolo, D., Furlan, C., Gallo, P., Gasbarrini, A., Giannelli, V., Grieco, S., Lambiase, L., Lattanzi, B., Lula, R., Malagnino, V., Manuelli, M., Miglioresi, L., Milana, M., Moretti, A., Nosotti, L., Palazzo, D., Romano, M., Sarrecchia, C., Sforza, D., Sorbo, M., Spaziante, M., Svicher, V., Tisone, G., Vespasiani-Gentilucci, U., D'Adamo, G., Mangia, A., Maida, I., Mura, M., Falconi, L., Di Giammartino, D., Di Maio, V, Cento, V, Lenci, I, Aragri, M, Rossi, P, Barbaliscia, S, Melis, M, Verucchi, G, Magni, C, Teti, E, Bertoli, A, Antonucci, F, Bellocchi, M, Micheli, V, Masetti, C, Landonio, S, Francioso, S, Santopaolo, F, Pellicelli, A, Calvaruso, V, Gianserra, L, Siciliano, M, Romagnoli, D, Cozzolongo, R, Grieco, A, Morisco, F, Merli, M, Brancaccio, G, Di Biagio, A, Loggi, E, Mastroianni, C, Pace Palitti, V, Tarquini, P, Puoti, M, Taliani, G, Sarmati, L, Picciotto, A, Vullo, V, Caporaso, N, Paoloni, M, Pasquazzi, C, Rizzardini, G, Parruti, G, Craxì, A, Babudieri, S, Andreoni, M, Angelico, M, Perno, C, Ceccherini-Silberstein, F, Velia C. Di Maio, Valeria Cento, Ilaria Lenci, Marianna Aragri, Piera Rossi, Silvia Barbaliscia, Michela Meli, Gabriella Verucchi, Carlo F. Magni, Elisabetta Teti, Ada Bertoli, Francesco Paolo Antonucci, Maria C. Bellocchi, Valeria Micheli, Chiara Masetti, Simona Landonio, Simona Francioso, Francesco Santopaolo, Adriano M. Pellicelli, Vincenza Calvaruso, Laura Gianserra, Massimo Siciliano, Dante Romagnoli, Raffaele Cozzolongo, Antonio Grieco, Jacopo Vecchiet, Filomena Morisco, Manuela Merli, Giuseppina Brancaccio, Antonio Di Biagio, Elisabetta Loggi, Claudio M. Mastroianni, Valeria Pace Palitti, Pierluigi Tarquini, Massimo Puoti, Gloria Taliani, Loredana Sarmati, Antonino Picciotto, Vincenzo Vullo, Nicola Caporaso, Maurizio Paoloni, Caterina Pasquazzi, Giuliano Rizzardini, Giustino Parruti, Antonio Craxì, Sergio Babudieri, Massimo Andreoni, Mario Angelico, Carlo F. Perno, Francesca Ceccherini-Silberstein, for the HCV Italian Resistance Network Study Group: [.., P. Andreone, E. Loggi, G. Verucchi, ], Di Maio, Velia C., Cento, Valeria, Lenci, Ilaria, Aragri, Marianna, Rossi, Piera, Barbaliscia, Silvia, Melis, Michela, Verucchi, Gabriella, Magni, Carlo F., Teti, Elisabetta, Bertoli, Ada, Antonucci, Francescopaolo, Bellocchi, Maria C., Micheli, Valeria, Masetti, Chiara, Landonio, Simona, Francioso, Simona, Santopaolo, Francesco, Pellicelli, Adriano M., Calvaruso, Vincenza, Gianserra, Laura, Siciliano, Massimo, Romagnoli, Dante, Cozzolongo, Raffaele, Grieco, Antonio, Vecchiet, Jacopo, Morisco, Filomena, Merli, Manuela, Brancaccio, Giuseppina, Di Biagio, Antonio, Loggi, Elisabetta, Mastroianni, Claudio M., Pace Palitti, Valeria, Tarquini, Pierluigi, Puoti, Massimo, Taliani, Gloria, Sarmati, Loredana, Picciotto, Antonino, Vullo, Vincenzo, Caporaso, Nicola, Paoloni, Maurizio, Pasquazzi, Caterina, Rizzardini, Giuliano, Parruti, Giustino, Craxã¬, Antonio, Babudieri, Sergio, Andreoni, Massimo, Angelico, Mario, Perno, Carlo F., Ceccherini-Silberstein, Francesca, Nicolini, L. A., Magni, C. F., Russo, M. L., Gaeta, G. B., Di Marco, V., Di Maio, V. C., Sorbo, M. C., Mura, M. S., Di Maio, Velia C, Magni, Carlo F, Bellocchi, Maria C, Pellicelli, Adriano M, Mastroianni, Claudio M, Craxì, Antonio, Perno, Carlo F, and Ceccherini Silberstein, Francesca
- Subjects
Male ,0301 basic medicine ,hepatitis C virus ,Sustained Virologic Response ,Sofosbuvir ,Hepacivirus ,Drug Resistance ,resistance-associated substitutions ,Viral Nonstructural Proteins ,VARIANTS ,NS5A ,medicine.disease_cause ,Gastroenterology ,chemistry.chemical_compound ,0302 clinical medicine ,Recurrence ,INFECTION ,antiviral therapy ,Medicine ,hepatitis C viru ,Viral ,Treatment Failure ,Chronic ,direct-acting antivirals ,resistance test ,hepatology ,biology ,GENOTYPE 1 ,virus diseases ,Middle Aged ,Settore MED/07 - Microbiologia e Microbiologia Clinica ,Hepatitis C ,Italy ,Combination ,Interferon ,Drug Therapy, Combination ,Female ,030211 gastroenterology & hepatology ,Author Keywords:antiviral therapy ,RIBAVIRIN ,Sequence Analysis ,Human ,medicine.drug ,medicine.medical_specialty ,Daclatasvir ,Genotype ,Hepatitis C virus ,Antiviral Agents ,LONG-TERM PERSISTENCE ,DACLATASVIR ,03 medical and health sciences ,Drug Therapy ,Aged ,Drug Resistance, Viral ,Hepatitis C, Chronic ,Humans ,Interferons ,Mutation ,Ribavirin ,Sequence Analysis, DNA ,Hepatology ,TREATMENT-NAIVE ,Internal medicine ,Antiviral Agent ,resistance-associated substitution ,direct-acting antiviral ,Hepaciviru ,resistance test KeyWords Plus:HEPATITIS-C VIRUS ,business.industry ,Viral Nonstructural Protein ,DNA ,biology.organism_classification ,Clinical trial ,030104 developmental biology ,SOFOSBUVIR ,chemistry ,Sequence Analysi ,Immunology ,business - Abstract
Background & Aims: Despite the excellent efficacy of direct-acting antivirals (DAA) reported in clinical trials, virological failures can occur, often associated with the development of resistance-associated substitutions (RASs). This study aimed to characterize the presence of clinically relevant RASs to all classes in real-life DAA failures. Methods: Of the 200 virological failures that were analyzed in 197 DAA-treated patients, 89 with pegylated-interferon+ribavirin (PegIFN+RBV) and 111 without (HCV-1a/1b/1g/2/3/4=58/83/1/6/24/25; 56.8% treatment experienced; 65.5% cirrhotic) were observed. Sanger sequencing of NS3/NS5A/NS5B was performed by home-made protocols, at failure (N= 200) and whenever possible at baseline (N= 70). Results: The majority of the virological failures were relapsers (57.0%), 22.5% breakthroughs, 20.5% non-responders. RAS prevalence varied according to IFN/RBV use, DAA class, failure type and HCV genotype/subtype. It was 73.0% in IFN group vs 49.5% in IFN free, with the highest prevalence of NS5A-RASs (96.1%), compared to NS3-RASs (75.9% with IFN, 70.5% without) and NS5B-RASs (66.6% with IFN, 20.4% without, in sofosbuvir failures). In the IFN-free group, RASs were higher in breakthrough/non-responders than in relapsers (90.5% vs 40.0%, P= 2 DAA classes showed multiclass resistance, including 11/11 NS3+NS5A failures. Furthermore, 20.0% of patients had baseline-RASs, which were always confirmed at failure. Conclusions: In our failure setting, RAS prevalence was remarkably high in all genes, with a partial exception for NS5B, whose limited resistance is still higher than previously reported. This multiclass resistance advocates for HCV resistance testing at failure, in all three genes for the best second-line therapeutic tailoring.
- Published
- 2017
- Full Text
- View/download PDF
22. Reactivation of Hepatitis B Virus With Immune-Escape Mutations After Ocrelizumab Treatment for Multiple Sclerosis
- Author
-
Ciardi, Maria R, primary, Iannetta, Marco, additional, Zingaropoli, Maria A, additional, Salpini, Romina, additional, Aragri, Marianna, additional, Annecca, Rosanna, additional, Pontecorvo, Simona, additional, Altieri, Marta, additional, Russo, Gianluca, additional, Svicher, Valentina, additional, Mastroianni, Claudio M, additional, and Vullo, Vincenzo, additional
- Published
- 2018
- Full Text
- View/download PDF
23. Additional file 3: Figure S1. of Implications of hepatitis C virus subtype 1a migration patterns for virus genetic sequencing policies in Italy
- Author
-
Cuypers, Lize, Vrancken, Bram, Fabeni, Lavinia, Marascio, Nadia, Cento, Valeria, Maio, Velia Di, Aragri, Marianna, Pineda-PeĂąa, Andrea, Schrooten, Yoeri, Laethem, Kristel Van, Balog, Daniel, FocĂ, Alfredo, Torti, Carlo, Nevens, Frederik, Perno, Carlo, Anne-Mieke Vandamme, and Ceccherini-Silberstein, Francesca
- Abstract
The thirteen highly supported Italian clusters indicated in the maximum clade credibility summary tree. The highly supported Italian-only clusters are highlighted in green, and the cluster number corresponding to the numbering in Table 3 is also detailed. The red background marks the dominant Q80K clade. The evolutionary distance bar at the bottom indicates the percentage of nucleotide substitutions per site along each lineage. (PDF 50 kb)
- Published
- 2017
- Full Text
- View/download PDF
24. Additional file 4: Table S2. of Implications of hepatitis C virus subtype 1a migration patterns for virus genetic sequencing policies in Italy
- Author
-
Cuypers, Lize, Vrancken, Bram, Fabeni, Lavinia, Marascio, Nadia, Cento, Valeria, Maio, Velia Di, Aragri, Marianna, Pineda-PeĂąa, Andrea, Schrooten, Yoeri, Laethem, Kristel Van, Balog, Daniel, FocĂ, Alfredo, Torti, Carlo, Nevens, Frederik, Perno, Carlo, Anne-Mieke Vandamme, and Ceccherini-Silberstein, Francesca
- Abstract
Geographical distribution of Italian Q80K lineages. For each Italian strain within the large Q80K clade, more detailed regional information is listed. (DOC 29Â kb)
- Published
- 2017
- Full Text
- View/download PDF
25. Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?
- Author
-
Di Maio, Velia Chiara, primary, Cento, Valeria, additional, Aragri, Marianna, additional, Paolucci, Stefania, additional, Pollicino, Teresa, additional, Coppola, Nicola, additional, Bruzzone, Bianca, additional, Ghisetti, Valeria, additional, Zazzi, Maurizio, additional, Brunetto, Maurizia, additional, Bertoli, Ada, additional, Barbaliscia, Silvia, additional, Galli, Silvia, additional, Gennari, William, additional, Baldanti, Fausto, additional, Raimondo, Giovanni, additional, Perno, Carlo Federico, additional, Ceccherini-Silberstein, Francesca, additional, Andreone, Pietro, additional, Andreoni, Massimo, additional, Angelico, Mario, additional, Babudieri, Sergio, additional, Barbarini, Giorgio, additional, Boccaccio, Vincenzo, additional, Boglione, Lucio, additional, Bolis, Matteo, additional, Bonora, Stefano, additional, Borghi, Vanni, additional, Brancaccio, Giuseppina, additional, Bruno, Savino, additional, Cacciatore, Pierluigi, additional, Calvaruso, Vincenza, additional, Caporaso, Nicola, additional, Ciaccio, Antonio, additional, Ciancio, Alessia, additional, Colombatto, Piero, additional, Cozzolongo, Raffaele, additional, Craxì, Antonio, additional, D'Ambrosio, Cecilia, additional, D'Ettorre, Gabriella, additional, De Luca, Andrea, additional, Di Biagio, Antonio, additional, Di Perri, Giovanni, additional, Francioso, Simona, additional, Gaeta, Giovanni Battista, additional, Giorgini, Alessia, additional, Grieco, Antonio, additional, Gubertini, Guido, additional, Gulminetti, Roberto, additional, Lambiase, Lara, additional, Lenci, Ilaria, additional, Lichtner, Miriam, additional, Maida, Ivana, additional, Marenco, Simona, additional, Marinaro, Letizia, additional, Maserati, Renato, additional, Masetti, Chiara, additional, Melis, Michela, additional, Meregalli, Elisa, additional, Micheli, Valeria, additional, Morisco, Filomena, additional, Niero, Fosca, additional, Nicolini, Laura Ambra, additional, Palitti, Valeria Pace, additional, Paoloni, Maurizio, additional, Parruti, Giustino, additional, Pasquazzi, Caterina, additional, Pellicelli, Adriano, additional, Polilli, Ennio, additional, Ponti, Maria Laura, additional, Puoti, Massimo, additional, Rendina, Maria, additional, Rizzardini, Giuliano, additional, Rossetti, Barbara, additional, Ruggiero, Tina, additional, Sangiovanni, Vincenzo, additional, Starace, Mario, additional, Sticchi, Laura, additional, Tarquini, Pierluigi, additional, Toniutto, Pierluigi, additional, and Vullo, Vincenzo, additional
- Published
- 2018
- Full Text
- View/download PDF
26. Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study
- Author
-
Cento, Valeria, primary, Aragri, Marianna, additional, Teti, Elisabetta, additional, Polilli, Ennio, additional, Bertoli, Ada, additional, Foroghi, Luca, additional, Barbaliscia, Silvia, additional, Di Maio, Velia Chiara, additional, Pieri, Alessandro, additional, Pace Palitti, Valeria, additional, Sarmati, Loredana, additional, Parruti, Giustino, additional, Andreoni, Massimo, additional, Perno, Carlo Federico, additional, and Ceccherini-Silberstein, Francesca, additional
- Published
- 2017
- Full Text
- View/download PDF
27. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies
- Author
-
Di Maio, Velia C, Cento, Valeria, Lenci, Ilaria, Aragri, Marianna, Rossi, Piera, Barbaliscia, Silvia, Melis, Michela, Verucchi, Gabriella, Magni, Carlo F, Teti, Elisabetta, Bertoli, Ada, Antonucci, Francescopaolo, Bellocchi, Maria C, Micheli, Valeria, Masetti, Chiara, Landonio, Simona, Francioso, Simona, Santopaolo, Francesco, Pellicelli, Adriano M, Calvaruso, Vincenza, Gianserra, Laura, Siciliano, Massimo, Romagnoli, Dante, Cozzolongo, Raffaele, Grieco, Antonio, Vecchiet, Jacopo, Morisco, Filomena, Merli, Manuela, Brancaccio, Giuseppina, Di Biagio, Antonio, Loggi, Elisabetta, Mastroianni, Claudio M, Pace Palitti, Valeria, Tarquini, Pierluigi, Puoti, Massimo, Taliani, Gloria, Sarmati, Loredana, Picciotto, Antonino, Vullo, Vincenzo, Caporaso, Nicola, Paoloni, Maurizio, Pasquazzi, Caterina, Rizzardini, Giuliano, Parruti, Giustino, Craxì, Antonio, Babudieri, Sergio, Andreoni, Massimo, Angelico, Mario, Perno, Carlo F, Ceccherini-Silberstein, Francesca, Grieco, Antonio (ORCID:0000-0002-0544-8993), Di Maio, Velia C, Cento, Valeria, Lenci, Ilaria, Aragri, Marianna, Rossi, Piera, Barbaliscia, Silvia, Melis, Michela, Verucchi, Gabriella, Magni, Carlo F, Teti, Elisabetta, Bertoli, Ada, Antonucci, Francescopaolo, Bellocchi, Maria C, Micheli, Valeria, Masetti, Chiara, Landonio, Simona, Francioso, Simona, Santopaolo, Francesco, Pellicelli, Adriano M, Calvaruso, Vincenza, Gianserra, Laura, Siciliano, Massimo, Romagnoli, Dante, Cozzolongo, Raffaele, Grieco, Antonio, Vecchiet, Jacopo, Morisco, Filomena, Merli, Manuela, Brancaccio, Giuseppina, Di Biagio, Antonio, Loggi, Elisabetta, Mastroianni, Claudio M, Pace Palitti, Valeria, Tarquini, Pierluigi, Puoti, Massimo, Taliani, Gloria, Sarmati, Loredana, Picciotto, Antonino, Vullo, Vincenzo, Caporaso, Nicola, Paoloni, Maurizio, Pasquazzi, Caterina, Rizzardini, Giuliano, Parruti, Giustino, Craxì, Antonio, Babudieri, Sergio, Andreoni, Massimo, Angelico, Mario, Perno, Carlo F, Ceccherini-Silberstein, Francesca, and Grieco, Antonio (ORCID:0000-0002-0544-8993)
- Abstract
BACKGROUND & AIMS: Despite the excellent efficacy of direct-acting antivirals (DAA) reported in clinical trials, virological failures can occur, often associated with the development of resistance-associated substitutions (RASs). This study aimed to characterize the presence of clinically relevant RASs to all classes in real-life DAA failures. METHODS: Of the 200 virological failures that were analyzed in 197 DAA-treated patients, 89 with pegylated-interferon+ribavirin (PegIFN+RBV) and 111 without (HCV-1a/1b/1g/2/3/4=58/83/1/6/24/25; 56.8% treatment experienced; 65.5% cirrhotic) were observed. Sanger sequencing of NS3/NS5A/NS5B was performed by home-made protocols, at failure (N=200) and whenever possible at baseline (N=70). RESULTS: The majority of the virological failures were relapsers (57.0%), 22.5% breakthroughs, 20.5% non-responders. RAS prevalence varied according to IFN/RBV use, DAA class, failure type and HCV genotype/subtype. It was 73.0% in IFN group vs 49.5% in IFN free, with the highest prevalence of NS5A-RASs (96.1%), compared to NS3-RASs (75.9% with IFN, 70.5% without) and NS5B-RASs (66.6% with IFN, 20.4% without, in sofosbuvir failures). In the IFN-free group, RASs were higher in breakthrough/non-responders than in relapsers (90.5% vs 40.0%, P<.001). Interestingly, 57.1% of DAA IFN-free non-responders had a misclassified genotype, and 3/4 sofosbuvir breakthroughs showed the major-RAS-S282T, while RAS-L159F was frequently found in sofosbuvir relapsers (18.2%). Notably, 9.0% of patients showed also extra target RASs, and 47.4% of patients treated with ≥2 DAA classes showed multiclass resistance, including 11/11 NS3+NS5A failures. Furthermore, 20.0% of patients had baseline-RASs, which were always confirmed at failure. CONCLUSIONS: In our failure setting, RAS prevalence was remarkably high in all genes, with a partial exception for NS5B, whose limited resistance is still higher than previously reported. This multiclass resistance advocates for HCV resis
- Published
- 2017
28. Implications of hepatitis C virus subtype 1a migration patterns for virus genetic sequencing policies in Italy
- Author
-
Cuypers, Lize, primary, Vrancken, Bram, additional, Fabeni, Lavinia, additional, Marascio, Nadia, additional, Cento, Valeria, additional, Di Maio, Velia Chiara, additional, Aragri, Marianna, additional, Pineda-Peña, Andrea Clemencia, additional, Schrooten, Yoeri, additional, Van Laethem, Kristel, additional, Balog, Daniel, additional, Focà, Alfredo, additional, Torti, Carlo, additional, Nevens, Frederik, additional, Perno, Carlo Federico, additional, Vandamme, Anne-Mieke, additional, and Ceccherini-Silberstein, Francesca, additional
- Published
- 2017
- Full Text
- View/download PDF
29. Consequences of inaccurate hepatitis C virus genotyping on the costs of prescription of direct antiviral agents in an Italian district
- Author
-
Polilli,Ennio, Cento,Valeria, Restelli,Umberto, Ceccherini-Silberstein,Francesca, Aragri,Marianna, Di Maio,Velia, Sciacca,Antonina, Santoleri,Fiorenzo, Fazii,Paolo, Costantini,Alberto, Perno,Carlo, Parruti,Giustino, Polilli,Ennio, Cento,Valeria, Restelli,Umberto, Ceccherini-Silberstein,Francesca, Aragri,Marianna, Di Maio,Velia, Sciacca,Antonina, Santoleri,Fiorenzo, Fazii,Paolo, Costantini,Alberto, Perno,Carlo, and Parruti,Giustino
- Abstract
Ennio Polilli,1 Valeria Cento,2 Umberto Restelli,3,4 Francesca Ceccherini-Silberstein,2 Marianna Aragri,2 Velia Chiara Di Maio,2 Antonina Sciacca,1 Fiorenzo Santoleri,5 Paolo Fazii,6 Alberto Costantini,5 Carlo Federico Perno,2 Giustino Parruti1 1Infectious Diseases Unit, Pescara General Hospital, Pescara, 2Department of Experimental Medicine and Surgery, University of Rome “Tor Vergata”, Rome, 3CREMS - Centre for Research on Health Economics, Social and Health Care Management, Carlo Cattaneo – LIUC University, Castellanza, Italy; 4School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; 5Hospital Pharmacy, Pescara General Hospital, 6Microbiology and Virology Unit, Pescara General Hospital, Pescara, Italy Abstract: Available commercial assays may yield inaccurate hepatitis C virus (HCV) genotype assignment in up to 10% of cases. We investigated the cost-effectiveness of re-evaluating HCV genotype by population sequencing, prior to choosing a direct acting antiviral (DAA) regimen. Between March and September 2015, HCV sequence analysis was performed in order to confirm commercial LiPA-HCV genotype (Versant® HCV Genotype 2.0) in patients eligible for treatment with DAAs. Out of 134 consecutive patients enrolled, sequencing yielded 21 (15.7%) cases of discordant results. For three cases of wrong genotype assignment, the putative reduction in efficacy was gauged between 15% and 40%. Among the eight cases for whom G1b was assigned by commercial assays instead of G1a, potentially suboptimal treatments would have been prescribed. Finally, for five patients with G1 and indeterminate subtype, the choice of regimens would have targeted the worst option, with a remarkable increase in costs, as in the case of the four mixed HCV infections for whom pan-genotypic regimens would have been mandatory. Precise assignment of HCV genotype and subtype by sequencing may, therefore, be more benef
- Published
- 2016
30. Consequences of inaccurate hepatitis C virus genotyping on the costs of prescription of direct antiviral agents in an Italian district
- Author
-
Parruti, Giustino, primary, Polilli, Ennio, additional, Cento, Valeria, additional, Restelli, Umberto, additional, Ceccherini-Silberstein, Francesca, additional, Aragri, Marianna, additional, Di Maio, Velia, additional, Sciacca, Antonina, additional, Santoleri, Fiorenzo, additional, Fazii, Paolo, additional, Costantini, Alberto, additional, and Perno, Carlo, additional
- Published
- 2016
- Full Text
- View/download PDF
31. Hepatitis C virus gene sequencing as a tool for precise genotyping in the era of new direct antiviral agents
- Author
-
Ceccherini Silberstein, Francesca, primary, Di Maio, Velia Chiara, additional, Aragri, Marianna, additional, Ciotti, Marco, additional, Cento, Valeria, additional, and Perno, Carlo Federico, additional
- Published
- 2015
- Full Text
- View/download PDF
32. Virological failures to direct acting antivirals (DAA) regimens in a real life setting show frequent resistance associated variants and may require re-treatment with unconventional strategies
- Author
-
Di Maio, Velia Chiara, Cento, Valeria, Lenci, Ilaria, Aragri, Marianna, Barbaliscia, Silvia, Francioso, Simona, Stefania Paolucci, Melis, Michela, Verucchi, Gabriella, Coppola, Nicola, Magni, Carlo F., Santopaolo, Francesco, Landonio, Simona, Ghisetti, Valeria, Starace, Mario, D Ambrosio, Cecilia, Calvaruso, Vincenzo, Caporasol, Nicola, Pasquazzi, Caterina, Maida, Ivana, Picciotto, Antonino, Di Biagio, Antonio, Sticchi, Laura, Cozzolongo, Raffaele, Romagnoli, Dante, Biolato, Marco, Vecchiet, Jacopo, D Ettorre, Gabriella, Merli, Manuela, Gaeta, Giovanni B., Ciancio, Alessia, Marinaro, Letizia, Andreone, Pietro, Barbarini, Giorgio, Gulminetti, Roberto, Palitti, Valeria Pace, Tarquini, Perluigi, Puoti, Massimo, Sangiovanni, Vincenzo, Paoloni, Maurizio, Babudieri, Sergio, Rizzardini, Giuliano, Bruno, Savino, Andreoni, Massimo, Pellicelli, Adriano M., Parruti, Giustino, Craxi, Antonio, Angelico, Mario, Perno, Carlo F., and Ceccherini-Silberstein, Francesca
33. CLINICAL AND VIROLOGICAL CHARACTERISTICS OF PATIENTS WITH CHRONIC HEPATITIS C AND FAILURE TO A GLECAPREVIR AND PIBRENTASVIR (G/P) TREATMENT IN REAL WORLD
- Author
-
Garcia Garcia, Federico, Dietz, Julia, Di Maio, Velia Chiara, Vermehren, Johannes, Salazar, Adolfo, Paolucci, Stefania, Mullhaupt, Beat, Coppola, Nicola, Cabezas, Joaquin, Stauber, Rudolf E., Puoti, Massimo, Arenas Ruiz-Tapiador, Juan Ignacio, Aragri, Marianna, Jimenez, Miguel, Callegaro, Annapaola, Pascasio Acevedo, Juan Manuel, Macias Rodriguez, Manuel Alberto, Rosales Zabal, Jose Miguel, Valeria Micheli, Gomez, Neus, Tellez, Francisco, Sarrazin, Christoph, and Silberstein, Francesca Ceccherini
34. Resistance-guided retreatment of HCV infected patients with a previous failure to an NS5A inhibitor-containing regimen: Italian real life experience
- Author
-
Di Maio, Velia Chiara, Aragri, Marianna, Masetti, Chiara, Stefania Paolucci, Bruzzone, Bianca, Degasperi, Elisabetta, Barbaliscia, Silvia, Pollicino, Teresa, Minichini, Carmine, Calvaruso, Vincenza, Rendina, Maria Grazia, Cento, Valeria, Teti, Elisabetta, Micheli, Valeria, Ghisetti, Valeria, Polilli, Ennio, Palitti, Valeria Pace, Landonio, Simona, Lenci, Ilaria, Donnarumma, Laura, Nicolini, Laura Ambra, Bertoli, Ada, Pasquazzi, Caterina, Callegaro, Maria Paola, Morisco, Filomena, Cenderrello, Giovanni, Marenco, Simona, Gulminetti, Roberto, Novati, Stefano, Andreone, Pietro, Ciancio, Alessia, Sangiovanni, Vincenzo, Cuomo, Nunzia, Morsica, Giulia, Borghi, Vanni, Maida, Ivana Rita, Brunetto, Maurizia, Cozzolongo, Raffaele, Santis, Adriano, Lichtner, Miriam, Babudieri, Sergio, Taliani, Gloria, Santantonio, Teresa, Paternoster, Claudio, Ganga, Roberto, Puoti, Massimo, Rizzardini, Giuliano, Pellicelli, Adriano, Lampertico, Pietro, Parruti, Giustino, Nicola, Coppola, Zazzi, Maurizio, Raimondo, Giovanni, Andreoni, Massimo, Craxi, Antonio, Mario, Angelico, Perno, Carlo Federico, and Ceccherini, Silberstein Francesca
35. ITALIAN REAL LIFE EXPERIENCE OF RESISTANCE-GUIDED RETREATMENT IN HCV INFECTED PATIENTS WHO PREVIOUSLY FAILED A NS5A INHIBITOR-CONTAINING REGIMEN
- Author
-
Di Maio, Velia Chiara, Aragri, Marianna, Masetti, Chiara, Paolucci, Stefania, Bruzzone, Bianca, Degasperi, Elisabetta, Barbaliscia, Silvia, Pollicino, Teresa, Minichini, Carmine, Calvaruso, Vincenza, Rendina, Maria, Cento, Valeria, Teti, Elisabetta, Valeria Micheli, Ghisetti, Valeria, Polilli, Ennio, Palitti, Valeria Pace, Landonio, Simona, Lenci, Ilaria, Francioso, Simona, Donnarumma, Laura, Nicolini, Laura Ambra, Bertoli, Ada, Starace, Mario, Pasquazzi, Caterina, Callegaro, Annapaola, Morisco, Filomena, Cenderello, Giovanni, Marenco, Simona, Gulminetti, Roberto, Novati, Stefano, Scuteri, Alessandra, Andreone, Pietro, Galli, Silvia, Ciancio, Alessia, Sangiovanni, Vincenzo, Cuomo, Nunzia, Raddi, Adriana, Morsica, Giulia, Hasson, Hamid, Borghi, Vanni, Maida, Ivana, Brunetto, Maurizia R., Colombatto, Piero, Cozzolongo, Raffaele Francesco, Santis, Adriano, Lichtner, Miriam, Babudieri, Sergio, Biliotti, Elisa, Taliani, Gloria, Santantonio, Teresa Antonia, Di Stefano, Mariantonietta, Paternoster, Claudio, Ganga, Roberto, Puoti, Massimo, Rizzardini, Giuliano, Pellicelli, Adriano, Milano, Eugenio, Mastroianni, Claudio, Licata, Anna, Di Lorenzo, Francesco, Giorgini, Alessia, Sighinolfi, Laura, Dentone, Chiara, Lleo, Ana, Rossetti, Barbara, Beretta, Ilaria, Lampertico, Pietro, Parruti, Giustino, Coppola, Nicola, Raimondo, Giovanni, Zazzi, Maurizio, Andreoni, Massimo, Angelico, Mario, Perno, Carlo Federico, Craxi, Antonio, and Silberstein, Francesca Ceccherini
36. Additional file 1: Table S1. of Implications of hepatitis C virus subtype 1a migration patterns for virus genetic sequencing policies in Italy
- Author
-
Cuypers, Lize, Vrancken, Bram, Fabeni, Lavinia, Marascio, Nadia, Cento, Valeria, Maio, Velia Di, Aragri, Marianna, Pineda-Peña, Andrea, Schrooten, Yoeri, Laethem, Kristel Van, Balog, Daniel, Focà, Alfredo, Torti, Carlo, Nevens, Frederik, Perno, Carlo, Anne-Mieke Vandamme, and Ceccherini-Silberstein, Francesca
- Subjects
3. Good health - Abstract
The country-wide distribution of Italian samples. Overall, 183 sequences were newly obtained from seven different regions. The publicly available data trace back to the work by de Luca et al. [14] (n = 67) and Paolluci et al. [51] (n = 30). The former samples have an unknown distribution among the Lazio, Lombardy, Tuscany and Apulia region. For the latter, it is only known that the patients visited the Fondazione IRCCS Policlinico San Matteo, Pavia, Lombardy. (DOC 31 kb)
37. Additional file 1: Table S1. of Implications of hepatitis C virus subtype 1a migration patterns for virus genetic sequencing policies in Italy
- Author
-
Cuypers, Lize, Vrancken, Bram, Fabeni, Lavinia, Marascio, Nadia, Cento, Valeria, Maio, Velia Di, Aragri, Marianna, Pineda-Peña, Andrea, Schrooten, Yoeri, Laethem, Kristel Van, Balog, Daniel, Focà, Alfredo, Torti, Carlo, Nevens, Frederik, Perno, Carlo, Anne-Mieke Vandamme, and Ceccherini-Silberstein, Francesca
- Subjects
3. Good health - Abstract
The country-wide distribution of Italian samples. Overall, 183 sequences were newly obtained from seven different regions. The publicly available data trace back to the work by de Luca et al. [14] (n = 67) and Paolluci et al. [51] (n = 30). The former samples have an unknown distribution among the Lazio, Lombardy, Tuscany and Apulia region. For the latter, it is only known that the patients visited the Fondazione IRCCS Policlinico San Matteo, Pavia, Lombardy. (DOC 31 kb)
38. DECLINE OF PREVALENCE OF RESISTANCE ASSOCIATED SUBSTITUTIONS TO NS3 AND NS5A INHIBITORS AT DAA-FAILURE IN HEPATITIS C VIRUS IN ITALY OVER THE YEARS 2015 TO 2018
- Author
-
Rossetti, Barbara, Redi, David, Di Maio, Velia Chiara, Aragri, Marianna, Paolucci, Stefania, Paglicci, Lorenzo, Masetti, Chiara, Bruzzone, Bianca, Minichini, Carmine, Montagnani, Francesca, Micheli, Valeria, Landonio, Simona, Zanelli, Giacomo, Degasperi, Elisabetta, Maserati, Renato, Maida, Ivana, Callegaro, Annapaola, Barbaliscia, Silvia, Bertoli, Ada, Paternoster, Claudio, Marenco, Simona, Morisco, Filomena, Calvaruso, Vincenza, Taliani, Gloria, Puoti, Massimo, Cenderello, Giovanni, Santis, Adriano, Lichtner, Miriam, Coppola, Nicola, Gulminetti, Roberto, Cento, Valeria, Rendina, Maria, Teti, Elisabetta, Parruti, Giustino, Ruggiero, Tina, Ghisetti, Valeria, Pasquazzi, Caterina, Nicolini, Laura Ambra, Vullo, Vincenzo, Pellicelli, Adriano, Prestileo, Tullio, Cozzolongo, Raffaele, Sangiovanni, Vincenzo, Biolato, Marco, Lenci, Ilaria, Licata, Anna, Ciaccio, Antonio, Palitti, Valeria Pace, Giorgini, Alessia, Cariti, Giuseppe, Ciancio, Alessia, Aghemo, Alessio, Borghi, Vanni, PIETRO ANDREONE, Brunetto, Maurizia R., Pollicino, Teresa, Santantonio, Teresa Antonia, Cuomo, Nunzia, Caudai, Cinzia, Babudieri, Sergio, Lampertico, Pietro, Gaeta, Giovanni Battista, Raimondo, Giovanni, Andreoni, Massimo, Rizzardini, Giuliano, Angelico, Mario, Perno, Carlo Federico, Craxi, Antonio, Zazzi, Maurizio, and Silberstein, Francesca Ceccherini
39. Natural NS3, NS5A and NS5B HCV resistance is common in real practice, differently associated to HCV genotypes and response to NS5A inhibitors
- Author
-
Cento, Valeria, Sorbo, Maria Chiara, Bertoli, Ada, Lenci, Ilaria, Polilli, Ennio, Masetti, Chiara, Gianserra, Laura, Teti, Elisabetta, Biliotti, Elisa, Magni, Carlo F., Aragri, Marianna, Micheli, Valeria, Melis, Michela, Nicolini, Laura A., Marenco, Simona, Calvaruso, Vincenza, Stefania Paolucci, Baldanti, Fausto, Morisco, Filomena, Siciliano, Massimo, Palitti, Valeria Pace, Andreone, Pietro, Bruzzone, Bianca, Coppola, Nicola, Ruggiero, Tina, Lichtner, Miriam, Menzaghi, Barbara, Romagnoli, Dante, Iapadre, Nerio, Di Maio, Velia Chiara, Leonardis, Francesco, Milana, Martina, Cacciatore, Pierluigi, Pieri, Alessandro, Sarmati, Loredana, Landonio, Simona, Gasbarrini, Antonio, Puoti, Massimo, Craxi, Antonio, Vullo, Vincenzo, Pellicelli, Adriano M., Babudieri, Sergio, Rizzardini, Giuliano, Taliani, Gloria, Andreoni, Massimo, Pasquazzi, Caterina, Parruti, Giustino, Angelico, Mario, Perno, Carlo F., and Ceccherini-Silberstein, Francesca
40. Characteristic and prevalence of NS3, NS5A and NS5B resistance associated substitutions in DAA-naive and DAA-failed HCV-3 patients in Italy
- Author
-
Di Maio, Velia Chiara, Barbaliscia, Silvia, Teti, Elisabetta, Lenci, Ilaria, Aragri, Marianna, Polilli, Ennio, Gianserra, Laura, Palitti, Valeria Pace, Bruzzone, Bianca, Paolucci, Stefania, Coppola, Nicola, Ruggiero, Tina, Pollicino, Teresa, Niero, Fosca, Valeria Micheli, Di Biagio, Antonio, Bertoli, Ada, Sticchi, Laura, Maida, Ivana, Francioso, Simona, Foroghi, Luca, Calvaruso, Vincenza, Morisco, Filomena, Lleo, Ana, Ciancio, Alessia, Maserati, Renato, Brancaccio, Giuseppina, Puoti, Massimo, Toniutto, Pierluigi, Vullo, Vincenzo, Aghemo, Alessio, Cariti, Giuseppe, Bonora, Stefano, Babudieri, Sergio, Gubertini, Guido A., Rendina, Maria, Pellicelli, Adriano M., Sangiovanni, Vincenzo, Ciaccio, Antonio, Taliani, Gloria, Raimondo, Giovanni, Craxi, Antonio, Pasquazzi, Caterina, Sarmati, Loredana, Parruti, Giustino, Angelico, Mario, Andreoni, Massimo, Cento, Valeria, Perno, Carlo Federico, and Ceccherini-Silberstein, Francesca
41. Reactivation of Hepatitis B Virus With Immune-Escape Mutations After Ocrelizumab Treatment for Multiple Sclerosis.
- Author
-
Ciardi, Maria R, Iannetta, Marco, Zingaropoli, Maria A, Salpini, Romina, Aragri, Marianna, Annecca, Rosanna, Pontecorvo, Simona, Altieri, Marta, Russo, Gianluca, Svicher, Valentina, Mastroianni, Claudio M, and Vullo, Vincenzo
- Abstract
Ocrelizumab is an anti-CD20 monoclonal antibody for the treatment of multiple sclerosis (MS) that is closely related to rituximab. We describe a case of hepatitis B virus (HBV) reactivation in an MS patient with resolved HBV infection receiving ocrelizumab. HBV reactivation was monitored with HBV-DNA and HBV surface antigen periodic assessment. Anti-HBV treatment with entecavir was started after HBV-DNA detection. Ocrelizumab can reactivate viral replication in patients with resolved HBV infection. HBV reactivation monitoring seems an effective and safe option for the management of these patients. More studies are needed to assess the optimal management of HBV reactivation in MS patients on ocrelizumab treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
42. A hyper-glycosylation of HBV surface antigen correlates with HBsAg-Negativity at immunosuppression-driven HBV reactivation in vivo and hinders HBsAg recognition in vitro
- Author
-
Francesca Ceccherini-Silberstein, Carlotta Cerva, Ada Bertoli, Carlo Federico Perno, Massimo Marignani, Miriam Lichtner, Aldo Marrone, L. Colagrossi, Jens Verheyen, Valentina Svicher, Katia Yu La Rosa, N. Iapadre, Constance Delaugerre, L. Piermatteo, Massimo Levrero, Sarah Maylin, Marianna Aragri, Nicola Coppola, Loredana Sarmati, Stefano Aquaro, A. Battisti, Romina Salpini, Laura Belloni, Massimo Andreoni, Mario Angelico, Patrizia Saccomandi, Filomena Morisco, Salpini, R., Piermatteo, L., Battisti, A., Colagrossi, L., Aragri, M., Rosa, K. Y. L., Bertoli, A., Saccomandi, P., Lichtner, M., Marignani, M., Maylin, S., Delaugerre, C., Morisco, F., Coppola, N., Marrone, A., Iapadre, N., Cerva, C., Aquaro, S., Angelico, M., Sarmati, L., Andreoni, M., Verheyen, J., Ceccherini-Silberstein, F., Levrero, M., Perno, C. F., Belloni, L., Svicher, V., Salpini, Romina, Piermatteo, Lorenzo, Battisti, Arianna, Colagrossi, Luna, Aragri, Marianna, Yu La Rosa, Katia, Bertoli, Ada, Saccomandi, Patrizia, Lichtner, Miriam, Marignani, Massimo, Maylin, Sarah, Delaugerre, Constance, Morisco, Filomena, Coppola, Nicola, Marrone, Aldo, Iapadre, Nerio, Cerva, Carlotta, Aquaro, Stefano, Angelico, Mario, Sarmati, Loredana, Andreoni, Massimo, Verheyen, Jen, Ceccherini-Silberstein, Francesca, Levrero, Massimo, Federico Perno, Carlo, Belloni, Laura, and Svicher, Valentina
- Subjects
0301 basic medicine ,Male ,HBsAg ,Glycosylation ,lcsh:QR1-502 ,Medizin ,medicine.disease_cause ,lcsh:Microbiology ,HBV ,HBV reactivation ,N-linked glycosylation ,0302 clinical medicine ,biology ,virus diseases ,Middle Aged ,Infectious Diseases ,030211 gastroenterology & hepatology ,Female ,Antibody ,Hepatitis B virus ,Article ,Cell Line ,03 medical and health sciences ,Antigen ,In vivo ,Virology ,medicine ,Humans ,Hepatitis B Antibodies ,Aged ,Immune Evasion ,Hepatitis ,Immunosuppression Therapy ,Hepatitis B Surface Antigens ,business.industry ,medicine.disease ,In vitro ,Settore MED/17 ,digestive system diseases ,030104 developmental biology ,Reinfection ,Mutation ,biology.protein ,Virus Activation ,business - Abstract
Immune-suppression driven Hepatitis B Virus (HBV)-reactivation poses serious concerns since it occurs in several clinical settings and can result in severe forms of hepatitis. Previous studies showed that HBV strains, circulating in patients with HBV-reactivation, are characterized by an enrichment of immune-escape mutations in HBV surface antigen (HBsAg). Here, we focused on specific immune-escape mutations associated with the acquisition of N-linked glycosylation sites in HBsAg (NLGSs). In particular, we investigated profiles of NLGSs in 47 patients with immunosuppression-driven HBV-reactivation and we evaluated their impact on HBsAg-antigenicity and HBV-replication in vitro. At HBV-reactivation, despite a median serum HBV-DNA of 6.7 [5.3&ndash, 8.0] logIU/mL, 23.4% of patients remained HBsAg-negative. HBsAg-negativity at HBV-reactivation correlated with the presence of >, 1 additional NLGSs (p <, 0.001). These NLGSs are located in the major hydrophilic region of HBsAg (known to be the target of antibodies) and resulted from the single mutation T115N, T117N, T123N, N114ins, and from the triple mutant S113N+T131N+M133T. In vitro, NLGSs strongly alter HBsAg antigenic properties and recognition by antibodies used in assays for HBsAg-quantification without affecting HBsAg-secretion and other parameters of HBV-replication. In conclusion, additional NLGSs correlate with HBsAg-negativity despite HBV-reactivation, and hamper HBsAg-antigenicity in vitro, supporting the role of NGSs in immune-escape and the importance of HBV-DNA for a proper diagnosis of HBV-reactivation.
- Published
- 2020
43. NS5A gene analysis by next generation sequencing in HCV nosocomial transmission clusters of HCV genotype 1b infected patients
- Author
-
Stefania Grimaudo, Lavinia Fabeni, Giuseppina Brancaccio, Carlo Federico Perno, Marco Cantone, L. Carioti, Antonio Pinto, M.C. Sorbo, Giovanni Battista Gaeta, Maria Concetta Bellocchi, Francesca Ceccherini-Silberstein, Velia Chiara Di Maio, Antonio Craxì, Vito Di Marco, Marianna Aragri, Ferdinando Frigeri, Fabrizio Bronte, Silvia Barbaliscia, Walter Mazzucco, Rosaria Maria Pipitone, Bellocchi, Maria Concetta, Aragri, Marianna, Carioti, Luca, Fabeni, Lavinia, Pipitone, Rosaria Maria, Brancaccio, Giuseppina, Sorbo, Maria Chiara, Barbaliscia, Silvia, Di Maio, Velia Chiara, Bronte, Fabrizio, Grimaudo, Stefania, Mazzucco, Walter, Frigeri, Ferdinando, Cantone, Marco, Pinto, Antonio, Perno, Carlo Federico, Craxì, Antonio, Gaeta, Giovanni Battista, Di Marco, Vito, and Ceccherini-Silberstein, Francesca
- Subjects
Male ,0301 basic medicine ,viruses ,Drug Resistance ,Hepacivirus ,Viral Nonstructural Proteins ,medicine.disease_cause ,Settore MED/42 - Igiene Generale E Applicata ,Gastroenterology ,Settore MED/07 ,chemistry.chemical_compound ,0302 clinical medicine ,Genotype 1b ,Medicine ,Viral ,lcsh:QH301-705.5 ,Phylogeny ,Cross Infection ,nosocomial transmission ,High-Throughput Nucleotide Sequencing ,virus diseases ,HCV ,NGS ,acute infection ,chronic infection ,sequencing ,Acute Disease ,Adult ,Amino Acid Substitution ,Antiviral Agents ,Blood Transfusion ,Chronic Disease ,Drug Resistance, Viral ,Female ,Genotype ,Hepatitis C ,Host-Pathogen Interactions ,Humans ,Interferons ,Middle Aged ,Polymorphism, Single Nucleotide ,beta-Thalassemia ,Single Nucleotide ,General Medicine ,030211 gastroenterology & hepatology ,medicine.medical_specialty ,Hepatitis C virus ,Viral quasispecies ,Article ,DNA sequencing ,03 medical and health sciences ,Internal medicine ,Polymorphism ,NS5A ,NS5B ,Gene ,Hepatology ,business.industry ,Nosocomial transmission ,biochemical phenomena, metabolism, and nutrition ,Virology ,digestive system diseases ,Chronic infection ,030104 developmental biology ,chemistry ,lcsh:Biology (General) ,business - Abstract
Background: The aim of the study was to investigate the intra-host variability through next-generation-sequencing (NGS) of the NS5A-gene in nosocomial transmission-clusters observed in two Italian hospitals among hepatitis C virus (HCV)-genotype-1b infected patients. Methods: HCV-sequencing was performed by Sanger-sequencing (NS3 + NS5A + NS5B) and by NGS (NS5A, MiSeq-Illumina) in 15 HCV-1b infected patients [five acute with onco-hematologic-disease and 10 (4/6 acute/chronic) with &beta, thalassemia]. Resistance-associated-substitutions (RAS) were analysed by Geno2pheno-algorithm. Nucleotide-sequence-variability (NSV, at 1%, 2%, 5%, 10% and 15% NGS-cutoffs) and Shannon entropy were estimated. Phylogenetic analysis was performed by Mega6-software and Bayesian-analysis. Results: Phylogenetic analysis showed five transmission-clusters: one involving four HCV-acute onco-hematologic-patients, one involving three HCV-chronic &beta, thalassemia-patients and three involving both HCV-acute and chronic &beta, thalassemia-patients. The NS5A-RAS Y93H was found in seven patients, distributed differently among chronic/acute patients involved in the same transmission-clusters, independently from the host-genetic IL-28-polymorphism. The intra-host NSV was higher in chronic-patients versus acute-patients, at all cutoffs analyzed (p <, 0.05). Even though Shannon-entropy was higher in chronic-patients, significantly higher values were observed only in chronic &beta, thalassemia-patients versus acute &beta, thalassemia-patients (p = 0.01). Conclusions: In nosocomial HCV transmission-clusters, the intra-host HCV quasispecies divergence in patients with acute-infection was very low in comparison to that in chronic-infection. The NS5A-RAS Y93H was often transmitted and distributed differently within the same transmission-clusters, independently from the IL-28-polymorphism.
- Published
- 2019
- Full Text
- View/download PDF
44. Consequences of inaccurate hepatitis C virus genotyping on the costs of prescription of direct antiviral agents in an Italian district.
- Author
-
Polilli E, Cento V, Restelli U, Ceccherini-Silberstein F, Aragri M, Di Maio VC, Sciacca A, Santoleri F, Fazii P, Costantini A, Perno CF, and Parruti G
- Abstract
Available commercial assays may yield inaccurate hepatitis C virus (HCV) genotype assignment in up to 10% of cases. We investigated the cost-effectiveness of re-evaluating HCV genotype by population sequencing, prior to choosing a direct acting antiviral (DAA) regimen. Between March and September 2015, HCV sequence analysis was performed in order to confirm commercial LiPA-HCV genotype (Versant
® HCV Genotype 2.0) in patients eligible for treatment with DAAs. Out of 134 consecutive patients enrolled, sequencing yielded 21 (15.7%) cases of discordant results. For three cases of wrong genotype assignment, the putative reduction in efficacy was gauged between 15% and 40%. Among the eight cases for whom G1b was assigned by commercial assays instead of G1a, potentially suboptimal treatments would have been prescribed. Finally, for five patients with G1 and indeterminate subtype, the choice of regimens would have targeted the worst option, with a remarkable increase in costs, as in the case of the four mixed HCV infections for whom pan-genotypic regimens would have been mandatory. Precise assignment of HCV genotype and subtype by sequencing may, therefore, be more beneficial than expected, until more potent pan-genotypic regimens are available for all patients.- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.